Understanding the Growth Hormone Peptide Landscape
Growth hormone peptide therapy has evolved significantly over the past decade. Where sermorelin once stood alone as the primary GHRH analog in clinical use, a more nuanced toolkit now exists — featuring peptides with longer durations of action, different receptor mechanisms, and important synergistic combinations that produce superior clinical outcomes to any single agent. Understanding this landscape helps patients and providers choose protocols aligned with specific goals.
CJC-1295: The Long-Acting GHRH Analog
CJC-1295 is a synthetic GHRH analog with a dramatically extended half-life compared to sermorelin. Sermorelin has a half-life of approximately 10–20 minutes (reflecting the natural GHRH pulse duration). CJC-1295 without DAC (Drug Affinity Complex) has a half-life of 30–60 minutes — still relatively brief. CJC-1295 with DAC extends to 6–8 days by binding irreversibly to albumin in the bloodstream — providing sustained GHRH-like stimulation rather than pulsatile release.
The clinical implication: CJC-1295 without DAC produces pulsatile GH release when combined with a secretagogue, mimicking physiological GH pulsatility. CJC-1295 with DAC produces more sustained, continuous GH elevation — preferred in some protocols for maximizing IGF-1 elevation but potentially less physiologically natural.
In clinical practice, CJC-1295 without DAC combined with ipamorelin is among the most widely used and best-tolerated peptide protocols in adult anti-aging and performance medicine.
Ipamorelin: The Selective GH Secretagogue
Ipamorelin activates the ghrelin receptor (GHS-R) — a distinct pathway from GHRH receptor signaling — to stimulate GH release. This dual-pathway approach (GHRH + ghrelin receptor) produces synergistic GH secretion that significantly exceeds what either agent produces alone.
Ipamorelin’s key advantages over earlier GH secretagogues (GHRP-2, GHRP-6): high selectivity for GH release without significant cortisol or prolactin elevation (GHRP-2 and GHRP-6 both elevate cortisol meaningfully); no appetite stimulation at clinical doses; minimal impact on LH, FSH, or thyroid hormones. This selectivity makes ipamorelin the preferred ghrelin receptor agonist for anti-aging and performance protocols where cortisol elevation is undesirable.
The CJC-1295 / Ipamorelin Combination Protocol
The combination of CJC-1295 (without DAC, typically 100–200 mcg) and ipamorelin (100–300 mcg) administered together as a single subcutaneous injection at bedtime is the most commonly prescribed growth hormone peptide protocol in clinical practice. The rationale:
- CJC-1295 stimulates GHRH receptors → triggers pituitary GH synthesis and release
- Ipamorelin simultaneously stimulates ghrelin receptors → amplifies the GH pulse through a complementary pathway
- The combined pulse is 2–3x greater than either agent alone
- Bedtime administration coincides with natural nocturnal GH peak → amplifies physiological GH release rather than creating an artificial peak out of sync with circadian rhythm
Clinical outcomes at 3–6 months: improved body composition (lean mass up, fat mass down), better sleep quality and depth, accelerated exercise recovery, improved skin texture, and enhanced energy and sense of wellbeing.
Other Relevant Peptides in Clinical Use
Tesamorelin: A GHRH analog FDA-approved for HIV-associated lipodystrophy, with strong evidence for visceral fat reduction — sometimes used off-label for metabolic fat reduction in patients who are not HIV-positive.
MK-677 (ibutamoren): An oral ghrelin receptor agonist — the only oral GH secretagogue with significant clinical data. Increases GH and IGF-1 significantly but also elevates cortisol and insulin, limiting its appeal for many patients compared to injectable peptide protocols.
Monitoring and Safety
Growth hormone peptide protocols are monitored with IGF-1 levels at 4–6 weeks and quarterly thereafter, with target of upper quartile of age-adjusted normal range. Contraindications include active malignancy (GH is mitogenic), pregnancy, and pituitary pathology.
To discuss a growth hormone peptide protocol tailored to your specific goals, call Multigen Wellness at (800) 259-0015.